User Settings
Article

Homo- vs. Heterozygotic Complement Factor H Y402H-Positive Patients With Occult CNV Subsequent to AMD - 1-Year Ranibizumab Treatment Monitoring by Means of Spectral and Time-Domain OCT

Sławomir Teper,Edward Wylęgała-2008-05-14
0

Chat with Paper

AI Agents for this Paper

No abstract available for this paper.

Keywords

RanibizumabFactor HMedicineOccultOphthalmologyComplement systemInternal medicineImmunology

Chat

Click to start Chat